Polaryx Therapeutics, Inc (NASDAQ: PLYX) is a clinical-stage biopharmaceutical company developing oral small molecule and gene therapies for lysosomal storage disorders (LSDs). The company generates no product revenue and funds operations through equity financings. As of December 31, 2025, Polaryx had an accumulated deficit of approximately $99.6 million and reported net cash used in operating activities of $3.9 million for the year ended December 31, 2025. Its lead candidate, PLX-200, is an oral, repurposed small molecule advancing toward a Phase 2 basket trial called SOTERIA, targeting CLN2, CLN3, Krabbe disease, and Sandhoff disease. The company received an FDA safe-to-proceed letter for the SOTERIA IND application in October 2025 and expects to initiate the trial in the second half of 2026. Management disclosed that existing capital is expected to fund operations only through the third quarter of 2026, citing going-concern conditions in the FY2025 financial statements. Headquarters, founding year, and exchange listing details beyond NASDAQ are not specified in the filing excerpts.

Revenue model

Polaryx has no product revenue. Operations are funded through equity financings. The company disclosed an accumulated deficit of approximately $99.6 million as of December 31, 2025, and anticipates continued operating losses and negative cash flows. Future revenue, if any, would depend on regulatory approval and commercialization of drug candidates, or potential licensing and milestone payments from collaborators.

Products and services

PLX-200: oral, repurposed small molecule, clinical-stage, advancing into Phase 2 SOTERIA basket trial for CLN2, CLN3, Krabbe disease, and Sandhoff disease (IND safe-to-proceed received October 2025). PLX-300: novel oral small molecule in IND application-enabling studies for lysosomal storage disorders. PLX-100: preclinical oral combination therapy comprising PLX-200 (PPARα agonist) and vitamin A (RXRα agonist), targeting LSDs. PLX-400: preclinical novel gene therapy for lysosomal storage disorders.

Customers and end markets

Target end market is patients with rare lysosomal storage disorders, including CLN2, CLN3, Krabbe disease, and Sandhoff disease. The SOTERIA trial targets indications representing approximately one quarter of the LSD population, per company disclosure in the FY2025 10-K. No commercial customers as of the filing date.

Value-chain role

Early-stage drug developer. Polaryx conducts research, preclinical studies, and clinical trials, relying on third-party contract research organizations (CROs), clinical trial sites, and contract manufacturers. The company licenses intellectual property and may seek collaborative development or sublicensing arrangements for commercialization, particularly in foreign markets.

Geographic exposure

Primary regulatory focus is the United States (FDA). The filing references potential future development and commercialization in foreign markets, subject to applicable foreign regulatory approvals. No commercial geographic revenue mix is disclosed.

Source: SEC 10-K, filed 2026-03-24

Industry: Pharmaceutical Preparations